Elhasi Sara, Astaneh Reyhaneh, Lavasanifar Afsaneh
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Alta., Canada.
Eur J Pharm Biopharm. 2007 Mar;65(3):406-13. doi: 10.1016/j.ejpb.2006.12.022. Epub 2007 Jan 18.
The purpose of this study was to investigate the solubilization of an amphiphilic drug, i.e, amiodarone (AMI) in methoxy poly(ethylene oxide)-block-poly(ester) micelles of different core structure. The effect of core-forming block structure as well as molecular weight, applied drug to polymer ratios and assembly condition on AMI solubilization; stability of the solubilized formulation upon dilution in phosphate buffer and the hemolytic activity of solubilized AMI against rat red blood cells were assessed and compared to those parameters for the commercial intravenous formulation of AMI. In general, polymeric micelles of different core structure were found to be more efficient in retaining their AMI content upon dilution than surfactant micelles in the commercial formulation of AMI for injection. Micelles with a poly(epsilon-caprolactone) (PCL) core were more efficient than poly(D,L-lactide) and poly(L-lactide) cores in the solubilization and stabilization of encapsulated AMI within the carrier. Encapsulation of AMI by methoxy poly(ethylene oxide)-block-poly(epsilon-caprolactone) (MePEO-b-PCL) micelles having higher PCL chains increased the level of AMI solubilization and decreased its hemolytic activity. Compared to O/W emulsion, application of solvent evaporation method led to higher encapsulation efficiency and lower hemolytic activity for AMI in micelles. An increase in the level of AMI added to the co-solvent evaporation process led to an increase in the solubilized AMI levels, but made the formulation more hemolytic. In conclusion, PEO-b-PCL micelles, particularly those with longer PCL chains, were found to be efficient carriers in encapsulating amphiphilic AMI, retaining encapsulated AMI within the carrier and reducing its hemolytic activity.
本研究的目的是研究一种两亲性药物,即胺碘酮(AMI)在具有不同核结构的甲氧基聚(环氧乙烷)-嵌段-聚(酯)胶束中的增溶情况。评估了成核嵌段结构以及分子量、药物与聚合物的比例和组装条件对AMI增溶的影响;评估了溶解制剂在磷酸盐缓冲液中稀释后的稳定性以及溶解的AMI对大鼠红细胞的溶血活性,并与AMI商业静脉制剂的这些参数进行了比较。一般来说,发现在AMI注射用商业制剂中,不同核结构的聚合物胶束在稀释后比表面活性剂胶束更有效地保留其AMI含量。具有聚(ε-己内酯)(PCL)核的胶束在载体中包封AMI的增溶和稳定方面比聚(D,L-丙交酯)和聚(L-丙交酯)核更有效。用具有较高PCL链的甲氧基聚(环氧乙烷)-嵌段-聚(ε-己内酯)(MePEO-b-PCL)胶束包封AMI可提高AMI的增溶水平并降低其溶血活性。与O/W乳液相比,采用溶剂蒸发法可提高胶束中AMI的包封效率并降低其溶血活性。增加添加到共溶剂蒸发过程中的AMI水平会导致溶解的AMI水平增加,但会使制剂更具溶血作用。总之,发现PEO-b-PCL胶束,特别是那些具有较长PCL链的胶束,是包封两亲性AMI、将包封的AMI保留在载体内并降低其溶血活性的有效载体。